It looks like you are using an older version of Internet Explorer which is not supported. We advise that you update your browser to the latest version of Microsoft Edge, or consider using other browsers such as Chrome, Firefox or Safari.

Choose another country

1. Acceptance and Use

  • The information and instructions provided to you by Novartis (as defined in Section 2 below) on this website do not replace the ENERZAIR® BREEZHALER® Package Leaflet (PL) and any instructions for use therein. Please refer to the PL and the instructions for use at all times for detailed information on this medicine.
  • This information does not offer or intend to offer personalised medical diagnosis or patient-specific treatment advice, which you should seek at all times with your own medical doctor or health care provider.
  • Your access to and use of this website www.breezhaler-asthma.eu/enerzair (“Site”) is subject to the existing legal relationship between you and Novartis, the following terms of use together with the Information (as defined in Section 3 below) provided in the PL.
  • By accessing and using this Site, you accept, without limitation or qualification, these terms of use and you unconditionally agree to comply with them and acknowledge that any other agreements regarding the use of this Site between you and Novartis are superseded and of no force or effect. If you do not agree to these terms of use, you must not use this Site.

2. Information about Us and this Site

This is the European Economic Area (EEA) training site for ENERZAIR® BREEZHALER®. This Site is checked, operated and updated by Novartis Pharma AG in collaboration with Novartis Europharm Limited (the holder of the EEA marketing authorisation of ENERZAIR® BREEZHALER®) and their European affiliates (collectively referred to as “Novartis”). We are a global healthcare company registered in Switzerland. Our main trading address is P.O. Box CH – 4002 Basel, Switzerland.

This Site is exclusively intended for use by adults who have been prescribed, in accordance with your country of residence’s laws and regulations, the use of ENERZAIR® BREEZHALER®. By using this Site you are confirming that you have been prescribed to use ENERZAIR® BREEZHALER®.

You should not construe anything on this Site as a promotion or advertisement for any medicinal product or for the use of any medicinal product that is not authorised by the laws and regulations of your country of residence.

3. Use of Information

You may only use this Site for the purpose of accessing the instructions for use of ENERZAIR® BREEZHALER® ("Purpose"), including any text, images, audio, and video (the "Information") provided that (i) use of such Information is for patient information, and non-commercial
or personal use only; and (ii) you may not distribute, modify, transmit, reuse, repost, or use the Information for commercial or social networking purposes, without prior written permission from Novartis.

No license to or right in the Information, or any copyright of Novartis or of any other party is granted or conferred to you. Any rights not
expressly granted herein are reserved by Novartis.

4. Copyright/Trademarks/Proprietary Rights

All content on this Site is the property of the Novartis group of companies and is protected by copyright.

You should assume that the product name appearing on this Site, whether or not appearing in large print, italics or with the trademark symbol ® are trademarks of Novartis. All product names published in italics on this Site are trademarks owned by or licensed to Novartis.

This Site may also contain or reference patents, proprietary information, technologies, products, processes or other proprietary rights of Novartis and/or other third parties. Novartis is the owner or the licensee of all intellectual property rights in this Site, and in the material published on it. These works are protected by copyright laws and treaties around the world. All such rights are reserved. No license to or right in any such trademarks, copyright, patents, trade secrets, technologies, products, processes and other proprietary rights of Novartis and/or other parties is granted to or conferred upon you. The use of these trademarks, of the company name Novartis and the company logo, except as permitted herein, is expressly prohibited.

5. Applicable Law, Consequences

These terms of use and your use of this Site shall be governed by the relevant EEA laws and regulations and the laws of your country without regard to its conflict of laws principles.

If Novartis becomes aware that you have violated any of the terms of use contained in this legal statement Novartis may immediately take corrective action. If Novartis has been injured by your violation Novartis may, in its sole discretion, seek to recover damages from you.

6. Revisions

Novartis reserves the right at any time to revise these terms of use by amending this page. Please note that we may make such changes at our own discretion and without prior announcement. By continuing to use this Site after any such changes, you unconditionally and fully understand, agree and accept to follow and be bound by these terms of use as changed. You should therefore periodically visit this page to review the then current terms of use to which you are bound and to note any changes or amendments that may have been made.

7. Severability

If any part or provision of these terms of use is found to be invalid, such invalidity shall not affect the enforceability or any other part or provision of these terms of use.

8. Waiver

Our failure to act with respect to a breach by you of these terms of use does not waive Novartis' right to act with respect to similar or other breaches.

9. Reporting of Side Effects

If you get any side effects, please talk to your doctor, pharmacist or nurse. By reporting side effects, you can help to provide more information on the safety of this medicine. You can report side effects directly via HPRA Pharmacovigilance, website: www.hpra.ie. Side effects could also be reported to Novartis preferably via www.report.novartis.com, or by email to [email protected] or by calling 01 2080 612.

Thank you for using this Site.